Clinical trials: Advanced Solid Tumors Cancer
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety, determine the recommended Phase 2 dose (RP2D), and assess preliminary clinical activity of GEN1044 in patients with solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT04424641
- Testing
- GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Tumors
A Study of IMC-A12 in Advanced Solid Tumors
In this study, participants will initially receive intravenous (IV) cixutumumab (IMC-A12) every 2 weeks or every 3 weeks for 6 weeks (one cycle).
- Trial name
- NCT01007032
- Testing
- Cixutumumab
- Where
- Japan
- Volunteers
- 21 people
- Sponsor
- Eli Lilly and Company
Cancer, Solid Tumor
Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
The purpose of this study is to determine the safety and tolerability of RXC004 as monotherapy and in combination with Nivolumab in patients with advanced malignancies.
- Trial name
- NCT03447470
- Testing
- RXC004, Nivolumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 46 people
- Sponsor
- Redx Pharma Ltd
Advanced Solid Tumor
Mirdametinib + BGB-3245 in Advanced Solid Tumors
A Phase 1/2a open-label, multicenter, dose escalation and expansion study of mirdametinib in combination with BGB-3245 in adult participants with histologically confirmed, advanced (American Joint Committee on Cancer (AJCC) Stage…
- Trial name
- NCT05580770
- Testing
- Mirdametinib 2mg, BGB-3245 5mg, Mirdametinib 3mg
- Where
- 8 sites in United States, Australia
- Volunteers
- 23 people
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Solid Cancers
A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study
This is a multicenter, open label extension study. Subjects who have completed treatment in the parent study of pertuzumab, either alone or with a combination agent, and who received at least one dose of pertuzumab in the parent…
- Trial name
- NCT00096941
- Testing
- Pertuzumab
- Volunteers
- 3 people
- Sponsor
- Genentech, Inc.
Solid Tumor, Adult
Study of ASTX029 in Subjects With Advanced Solid Tumors
This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029 administered orally to participants with advanced…
- Trial name
- NCT03520075
- Testing
- ASTX029
- Where
- 31 sites in United States, France and 2 more
- Volunteers
- 192 people
- Sponsor
- Taiho Oncology, Inc.
Advanced Solid Tumors
A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002)
The study determined the recommended Phase 2 loading and maintenance doses and dose schedules for administering dalotuzumab using dose-limiting toxicities (DLTs) observed during the entire treatment period (Up to 18 months).
- Trial name
- NCT00635778
- Testing
- dalotuzumab
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasm Metastasis, Advanced Tumors
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
This is a study in adults with various types of advanced cancer. The purpose of the study is to test a medicine called BI 754091 in combination with several other cancer medicines. BI 754091 is an immunotherapy.
- Conditions
- Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors
- Trial name
- NCT03697304
- Testing
- Ezabenlimab, BI 754111, BI 836880
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 211 people
- Sponsor
- Boehringer Ingelheim
HIV, Cancer
Durvalumab in HIV-1 Patients With Solid Tumors
The proposal is a phase II clinical study designed to assess the feasibility of durvalumab (MEDI4736) in HIV-1-infected individuals with solid tumors.
- Trial name
- NCT03094286
- Testing
- Durvalumab
- Where
- 8 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Spanish Lung Cancer Group
Solid Tumor, Adult, Triple Negative Breast Cancer
AVID100 in Advanced Epithelial Carcinomas
Approximately 90 male and female patients with documented solid tumor malignancies of epithelial origin that are locally advanced or metastatic, and either refractory to standard therapy or for whom no standard therapy is…
- Conditions
- Solid Tumor, Adult, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT03094169
- Testing
- AVID100 IV
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Formation Biologics
Breast Cancer, Colorectal Cancer
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.
- Conditions
- Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma
- Trial name
- NCT03422679
- Testing
- CB-103
- Where
- 17 sites in United States, France and 4 more
- Volunteers
- 79 people
- Sponsor
- Cellestia Biotech AG
Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.
- Conditions
- Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Unresectable Melanoma
- Trial name
- NCT03679767
- Testing
- Retifanlimab
- Where
- 52 sites in United States, Austria and 6 more
- Volunteers
- 121 people
- Sponsor
- Incyte Corporation
Malignant Solid Tumor
A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors
The purpose of this study is to assess the effect of concomitant ramucirumab on the pharmacokinetics of docetaxel in participants with advanced malignant solid tumors.
- Trial name
- NCT01567163
- Testing
- Ramucirumab, Docetaxel
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Eli Lilly and Company
Advanced Malignant Solid Neoplasm
CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study
This phase I/II trial investigates the side effects and how well CD24Fc works in treating immune related adverse events in patients with solid tumors that have spread to other places in the body (advanced).
- Trial name
- NCT04552704
- Testing
- CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Tianhong Li
Advanced Solid Tumors
An Open-Label Pharmacokinetics and Safety Study of Talazoparib
This trial will investigate the pharmacokinetics (PK) and safety of talazoparib in patients with advanced solid tumors and impaired renal function.
- Trial name
- NCT02997163
- Testing
- Talazoparib
- Where
- 10 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Pfizer
Advanced Solid Tumor
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
Prospective, open-label, two-way crossover, phase Ib drug-drug interaction study in patients with advanced solid tumors. The study consisting of two lurbinectedin cycles, one cycle in combination with bosentan and one cycle as…
- Trial name
- NCT05072106
- Testing
- Lurbinectedin, Bosentan
- Where
- 2 sites in Spain
- Volunteers
- 11 people
- Sponsor
- PharmaMar
Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion
Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
This was an open-label, multicenter, nonrandomized Phase 1 and 2 clinical trial evaluating various combinations of surzebiclimab (BGB-A425) and/or alcestobart (LBL-007) with tislelizumab.
- Conditions
- Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
- Trial name
- NCT03744468
- Testing
- Surzebiclimab, Tislelizumab, Alcestobart
- Where
- 40 sites in United States, Australia and 4 more
- Volunteers
- 147 people
- Sponsor
- BeiGene
Advanced Malignant Solid Neoplasm, Glioblastoma
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
This phase II trial studies how well olaparib works in treating patients with glioma, cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations that has spread from where it first started (primary site) to other places in…
- Conditions
- Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma
- Trial name
- NCT03212274
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 51 sites in United States
- Volunteers
- 89 people
- Sponsor
- National Cancer Institute (NCI)
Oncology, MET Gene Amplification
Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies
This is the first study to test Sym015 in humans. The primary purpose of this study is to see if Sym015 is safe and effective for patients with advanced solid tumor malignancies without available therapeutic options.
- Conditions
- Oncology, MET Gene Amplification, NSCLC, MET Gene Mutation
- Trial name
- NCT02648724
- Testing
- Sym015
- Where
- 27 sites in United States, Denmark and 4 more
- Volunteers
- 57 people
- Sponsor
- Symphogen A/S
Advanced Solid Tumors
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Multicenter, open-label, exploratory, phase II clinical trial to evaluate the efficacy and safety of PM01183 in previously treated patients with advanced solid tumors
- Trial name
- NCT02454972
- Testing
- lurbinectedin (PM01183)
- Where
- 40 sites in United States, Belgium and 7 more
- Volunteers
- 345 people
- Sponsor
- PharmaMar